Abstract
Under reporting is the major drawback of adverse drug reaction. We aimed to conduct a systematic review of adverse reaction monitoring and reporting system in order to assess the effective reporting of adverse drug reaction to reduce the underreporting. The rapid development of new drugs to diagnose and treat human illness increases the incidence of adverse reactions which produces mortality and morbidity. 0.40% of patients were identified as having ADRs which are directly linked with high costs. ADR is considered to be the fourth and sixth leading cause of death. Type A ADRS are predictable from their pharmacology and are dose dependent, they are readily reversible on reducing dose or withdrawing treatment. Type B ADRs are usually bizarre reactions unrelated to the conventional pharmacology of the drug and occur only in susceptible individuals. There are certain approaches which aids in the evaluation of assessment of adverse events using certain scales. The National Pharmacovigilance Advisory Committee (NPAC) monitors the performance of pharmacovigilance zones. The reporting Of ADR should be done to The Central Drugs Standard Control Organization (CDSCO). It is not only important to educate the patient but also the health care professionals about the use and possible events of the drug. Reporting of adverse drug reaction has added a great value by improving the accuracy and efficiency for evaluation of unwanted effects. The health care professionals should be made aware of pharmacovigilance programs.
